Empirically Evaluating Decision-Analytic Models

National Institute of Health and Clinical Excellence Edejer, 2003 Gold, 1996 Chilcott, 2003, The role of modelling in prioritising and planning clinical trials, Health Technol Assess, 7, 1, 10.3310/hta7230 Giorgi Rossi, 2008, Re: cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination, J Natl Cancer Inst, 100, 1654, 10.1093/jnci/djn367 Goldhaber-Fiebert, 2007, Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination, Popul Health Metr, 5, 11, 10.1186/1478-7954-5-11 Goldhaber-Fiebert, 2008, Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination, J Natl Cancer Inst, 100, 308, 10.1093/jnci/djn019 Stout, 2008, Trade-offs in cervical cancer prevention: balancing benefits and risks, Arch Intern Med, 168, 1881, 10.1001/archinte.168.17.1881 Hunink, 2001 Stout, 2009, Calibration methods used in cancer simulation models and suggested reporting guidelines, Pharmacoeconomics, 27, 533, 10.2165/11314830-000000000-00000 Eddy, 2003, Validation of the archimedes diabetes model, Diabetes Care, 26, 3102, 10.2337/diacare.26.11.3102 Palmer, 2004, Validation of the CORE Diabetes Model against epidemiological and clinical studies, Curr Med Res Opin, 20, S27, 10.1185/030079904X2006 Ramsey, 2000, Simulation modeling of outcomes and cost effectiveness, Hematol Oncol Clin North Am, 14, 925, 10.1016/S0889-8588(05)70319-1 Sornette, 2007, Algorithm for model validation: theory and applications, Proc Natl Acad Sci U S A, 104, 6562, 10.1073/pnas.0611677104 American Diabetes Association Consensus Panel, 2004, Guidelines for computer modeling of diabetes and its complications, Diabetes Care, 27, 2262, 10.2337/diacare.27.9.2262 The Mount Hood 4 Modeling Group, 2007, Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting, Diabetes Care, 30, 1638, 10.2337/dc07-9919 Bagust, 2005, Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel, Diabetes Care, 28, 500, 10.2337/diacare.28.2.500 Drummond, 2000, Health economic models: a question of balance—summary of an open discussion on the pharmacoeconomic evaluation of non-steroidal anti-inflammatory drugs, Rheumatology (Oxford), 39, 29, 10.1093/rheumatology/39.suppl_2.29 Hammerschmidt, 2003, Validation of health economic models: the example of EVITA, Value Health, 6, 551, 10.1046/j.1524-4733.2003.65241.x Hay, 2004, Evaluation and review of pharmacoeconomic models, Expert Opin Pharmacother, 5, 1867, 10.1517/14656566.5.9.1867 Institute of Medicine (US) Committee for Evaluating Medical Technologies in Clinical Use, Institute of Medicine (US) Division of Health Sciences Policy, Institute of Medicine (US) Division of Health Promotion and Disease Prevention, 1985 Kim, 2008, Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches, Pharmacoeconomics, 26, 191, 10.2165/00019053-200826030-00004 Kohn, 1995, Achieving credibility in risk assessment models, Toxicol Lett, 79, 107, 10.1016/0378-4274(95)03362-O Marshall, 2008, Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada, Pharmacoeconomics, 26, 477, 10.2165/00019053-200826060-00003 McCabe, 2000, Testing the validity of cost-effectiveness models, Pharmacoeconomics, 17, 501, 10.2165/00019053-200017050-00007 Newall, 2007, Cost-effectiveness analyses of human papillomavirus vaccination, Lancet Infect Dis, 7, 289, 10.1016/S1473-3099(07)70083-X Oreskes, 1998, Evaluation (not validation) of quantitative models, Environ Health Perspect, 106, 1453, 10.1289/ehp.98106s61453 Russell, 1999, Modelling for cost-effectiveness analysis, Stat Med, 18, 3235, 10.1002/(SICI)1097-0258(19991215)18:23<3235::AID-SIM313>3.0.CO;2-6 Sculpher, 2000, Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application, Pharmacoeconomics, 17, 461, 10.2165/00019053-200017050-00005 Taylor-Robinson, 2008, Policy-makers' attitudes to decision support models for coronary heart disease: a qualitative study, J Health Serv Res Policy, 13, 209, 10.1258/jhsrp.2008.008045 Unal, 2006, Coronary heart disease policy models: a systematic review, BMC Public Health, 6, 213, 10.1186/1471-2458-6-213 Weinstein, 2003, Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies, Value Health, 6, 9, 10.1046/j.1524-4733.2003.00234.x Weinstein, 2001, Modeling for health care and other policy decisions: uses, roles, and validity, Value Health, 4, 348, 10.1046/j.1524-4733.2001.45061.x Hodges, 1992 Arveux, 2003, Building a model to determine the cost-effectiveness of breast cancer screening in France, Eur J Cancer Care (Engl), 12, 143, 10.1046/j.1365-2354.2003.00373.x Baker, 1998, Use of a mathematical model to evaluate breast cancer screening policy, Health Care Manag Sci, 1, 103, 10.1023/A:1019046619402 Borg, 2008, The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model, Acta Oncol, 47, 1009, 10.1080/02841860701744498 Brown, 2004, The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia, Sex Transm Infect, 80, i19, 10.1136/sti.2004.010165 Chang, 2007, Estimation and prediction system for multi-state disease process: application to analysis of organized screening regime, J Eval Clin Pract, 13, 867 Chen, 2000, Estimation of sojourn time in chronic disease screening without data on interval cases, Biometrics, 56, 167, 10.1111/j.0006-341X.2000.00167.x Cook, 2004, Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia, Pharmacoeconomics, 22, 37, 10.2165/00019053-200422003-00005 Custer, 2005, Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply, Med Decis Making, 25, 571, 10.1177/0272989X05280557 Dasbach, 2008, The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan, Asian Pac J Cancer Prev, 9, 459 Dedes, 2007, Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial, Ann Oncol, 18, 1493, 10.1093/annonc/mdm185 Etzioni, 2008, Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach, Med Decis Making, 28, 323, 10.1177/0272989X07312719 Grover, 1999, Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events, Arch Intern Med, 159, 593, 10.1001/archinte.159.6.593 Grover, 2000, Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated?, Circulation, 102, 722, 10.1161/01.CIR.102.7.722 Grover, 1998, Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention, Arch Intern Med, 158, 655, 10.1001/archinte.158.6.655 Hoffmann, 2004, Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease, Eur J Health Econ, 5, 129, 10.1007/s10198-003-0211-4 Holman, 2006, PROactive study, Lancet, 367, 25, 10.1016/S0140-6736(06)67914-2 Hu, 2007, The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico, Plos ONE, 2, e750, 10.1371/journal.pone.0000750 Ishida, 2008, Validating a Markov model of treatment for hepatitis C virus-related hepatocellular carcinoma, Methods Inf Med, 47, 529, 10.3414/ME9124 Krahn, 1998, Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program, Am J Public Health, 88, 1638, 10.2105/AJPH.88.11.1638 Kulkarni, 2007, Optimal management of high-risk T1G3 bladder cancer: a decision analysis, Plos Med, 4, e284, 10.1371/journal.pmed.0040284 Lejeune, 2003, A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer, Eur J Cancer Prev, 12, 77, 10.1097/00008469-200302000-00012 Moeremans, 2004, Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer, Value Health, 7, 472, 10.1111/j.1524-4733.2004.74010.x Niessen, 2003, Lifetime health effects and costs of diabetes treatment, Neth J Med, 61, 55 Oostenbrink, 2005, Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries, Value Health, 8, 32, 10.1111/j.1524-4733.2005.03086.x Ortegon, 2004, Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis, Diabetes Care, 27, 901, 10.2337/diacare.27.4.901 Perreault, 2005, Validation of a decision model for preventive pharmacological strategies in postmenopausal women, Eur J Epidemiol, 20, 89, 10.1007/s10654-004-9478-8 Saab, 2002, Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?, Liver Transpl, 8, 449, 10.1053/jlts.2002.32717 Sagmeister, 2002, Cost-effectiveness of cadaveric and living-donor liver transplantation, Transplantation, 73, 616, 10.1097/00007890-200202270-00025 Schau, 2003, Development and validation of a model to estimate stroke incidence in a population, J Stroke Cerebrovasc Dis, 12, 22, 10.1053/jscd.2003.6 Sendi, 1999, Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study, J Eval Clin Pract, 5, 283, 10.1046/j.1365-2753.1999.00174.x Shwartz, 1978, An analysis of the benefits of serial screening for breast cancer based upon a mathematical model of the disease, Cancer, 41, 1550, 10.1002/1097-0142(197804)41:4<1550::AID-CNCR2820410445>3.0.CO;2-2 Siebert, 2006, The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany, Eur J Public Health, 16, 185, 10.1093/eurpub/cki163 Skedgel, 2007, Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole, Breast Cancer Res Treat, 101, 325, 10.1007/s10549-006-9299-4 Smolen, 2007, Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis, Value Health, 10, 489, 10.1111/j.1524-4733.2007.00204.x Stahl, 2007, Assessing emerging technologies—the case of organ replacement technologies: volume, durability, cost, Int J Technol Assess Health Care, 23, 331, 10.1017/S0266462307070535 Thompson, 2002, Validating benefit and cost estimates: the case of airbag regulation, Risk Anal, 22, 803, 10.1111/0272-4332.00070 Tosteson, 2001, Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions, Osteoporos Int, 12, 849, 10.1007/s001980170036 Unal, 2004, Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000, Circulation, 109, 1101, 10.1161/01.CIR.0000118498.35499.B2 Urban, 1997, Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening, Control Clin Trials, 18, 251, 10.1016/S0197-2456(96)00233-4 Van Laere, 2008, The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism, Eur J Nucl Med Mol Imaging, 35, 1367, 10.1007/s00259-008-0777-2 Welsing, 2006, The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis, Pharmacoeconomics, 24, 1011, 10.2165/00019053-200624100-00008 Munoz, 2006, Chapter 1: HPV in the etiology of human cancer, Vaccine, 24, S3/1 Aareleid, 1993, Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population, Eur J Cancer, 29A, 745, 10.1016/S0959-8049(05)80359-4 Devesa, 1987, Cancer incidence and mortality trends among whites in the United States, 1947–84, J Natl Cancer Inst, 79, 701 Macgregor, 1994, Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease, BMJ, 308, 1407, 10.1136/bmj.308.6941.1407 Mahlck, 1994, Pap smear screening and changes in cervical cancer mortality in Sweden, Int J Gynaecol Obstet, 44, 267, 10.1016/0020-7292(94)90177-5 Cuzick, 2006, Chapter 10: new dimensions in cervical cancer screening, Vaccine, 24, S3 Inglis, 2006, Chapter 11: HPV vaccines: commercial research & development, Vaccine, 24, S3/99 McCredie, 2008, Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study, Lancet Oncol, 9, 425, 10.1016/S1470-2045(08)70103-7 Statistic New Zealand